- In January 2026, Lightmatter announced a collaboration with Synopsys to integrate Synopsys 224G SerDes and UCIe IP for 3nm into its Passage 3D co-packaged optics platform, aiming to create a low-latency, high-bandwidth link between AI accelerators and Lightmatter’s photonic engine.
- This tie-up highlights how Synopsys’ AI-focused EDA and IP portfolio is being pulled directly into cutting-edge optical interconnects for next-generation AI infrastructure, reinforcing its role in enabling advanced chip-to-photonics design.
- We’ll now examine how this AI-infrastructure collaboration with Lightmatter shapes Synopsys’ investment narrative, particularly around its advanced IP ecosystem.
AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
What Is Synopsys' Investment Narrative?
For Synopsys to make sense in a portfolio, you have to believe in its role as a core “picks-and-shovels” provider to advanced chip and AI system design, even with a rich valuation and recent share price pullback. The Lightmatter collaboration fits squarely into that thesis: it showcases Synopsys IP and AI-enabled tools at the bleeding edge of optical interconnects, but is unlikely to shift near-term catalysts as much as the upcoming Q1 2026 earnings, progress on the Ansys integration, or how the market reassesses margin risk from new AI design tools after the recent 8.5% share price drop and rising short interest. If anything, Lightmatter modestly reinforces the IP ecosystem story while the main risks remain: earnings quality, premium multiples, and investor concern over future competitive pressure.
However, one risk in particular could catch some shareholders off guard if they miss it. Synopsys' share price has been on the slide but might be up to 7% below fair value. Find out if it's a bargain.Exploring Other Perspectives
Explore 6 other fair value estimates on Synopsys - why the stock might be worth 6% less than the current price!
Build Your Own Synopsys Narrative
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
- A great starting point for your Synopsys research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Synopsys research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Synopsys' overall financial health at a glance.
Seeking Other Investments?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
- Find 55 companies with promising cash flow potential yet trading below their fair value.
- The future of work is here. Discover the 28 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Uncover the next big thing with 25 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com